(0.15%) 5 139.00 points
(0.08%) 38 472 points
(0.24%) 17 888 points
(-0.29%) $83.61
(1.82%) $1.958
(0.10%) $2 349.50
(0.39%) $27.64
(1.42%) $935.15
(-0.10%) $0.934
(-0.23%) $11.00
(-0.19%) $0.799
(1.29%) $93.06
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 7.74%
@ $9.92
发出时间: 15 Feb 2024 @ 04:58
回报率: -33.17%
上一信号: Feb 14 - 02:33
上一信号:
回报率: 2.06 %
Live Chart Being Loaded With Signals
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments...
Stats | |
---|---|
今日成交量 | 421 184 |
平均成交量 | 379 898 |
市值 | 289.76M |
EPS | $0 ( 2024-03-05 ) |
下一个收益日期 | ( $-0.100 ) 2024-05-02 |
Last Dividend | $1.000 ( 2010-01-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -13.00 |
ATR14 | $0.0100 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-16 | Zaderej Karen L. | Buy | 84 847 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 975 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 166 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 500 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 086 | Common Stock |
INSIDER POWER |
---|
41.83 |
Last 98 transactions |
Buy: 1 200 055 | Sell: 468 598 |
音量 相关性
AxoGen Inc 相关性 - 货币/商品
AxoGen Inc 财务报表
Annual | 2023 |
营收: | $159.01M |
毛利润: | $127.87M (80.42 %) |
EPS: | $-0.510 |
FY | 2023 |
营收: | $159.01M |
毛利润: | $127.87M (80.42 %) |
EPS: | $-0.510 |
FY | 2022 |
营收: | $138.58M |
毛利润: | $114.44M (82.58 %) |
EPS: | $-0.650 |
FY | 2021 |
营收: | $127.36M |
毛利润: | $104.43M (81.99 %) |
EPS: | $-0.675 |
Financial Reports:
No articles found.
AxoGen Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0417 | 1992-07-10 |
Last Dividend | $1.000 | 2010-01-27 |
Next Dividend | $0 | N/A |
Payout Date | 2010-02-12 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $1.102 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.23 | -- |
Div. Sustainability Score | 1.724 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1992 | $0.0417 | 0.45% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0.0600 | 4.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $1.000 | 24.10% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.134 | 1.500 | -2.69 | -4.03 | [0 - 0.5] |
returnOnAssetsTTM | -0.108 | 1.200 | -3.62 | -4.34 | [0 - 0.3] |
returnOnEquityTTM | -0.220 | 1.500 | -3.56 | -5.33 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.89 | 0.800 | 0.540 | 0.432 | [1 - 3] |
quickRatioTTM | 2.04 | 0.800 | 2.69 | 2.15 | [0.8 - 2.5] |
cashRatioTTM | 1.217 | 1.500 | 4.35 | 6.53 | [0.2 - 2] |
debtRatioTTM | 0.245 | -1.500 | 5.92 | -8.88 | [0 - 0.6] |
interestCoverageTTM | -7.45 | 1.000 | -3.87 | -3.87 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.133 | 2.00 | -0.0443 | -0.0885 | [0 - 30] |
freeCashFlowPerShareTTM | -0.479 | 2.00 | -0.240 | -0.479 | [0 - 20] |
debtEquityRatioTTM | 0.503 | -1.500 | 7.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.804 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.135 | 1.000 | -4.70 | -4.70 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.119 | 1.000 | -1.771 | -1.771 | [0.2 - 2] |
assetTurnoverTTM | 0.808 | 0.800 | 7.95 | 6.36 | [0.5 - 2] |
Total Score | 1.724 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -13.37 | 1.000 | -1.451 | 0 | [1 - 100] |
returnOnEquityTTM | -0.220 | 2.50 | -2.29 | -5.33 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.479 | 2.00 | -0.160 | -0.479 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.133 | 2.00 | -0.0443 | -0.0885 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.393 | 1.500 | -5.95 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0359 | 1.000 | -3.40 | 0 | [0.1 - 0.5] |
Total Score | -1.990 |
AxoGen Inc
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。